Hims & Hers Health Stock Stumbles After Earnings. Here’s Why.

Hims & Hers Health is a telehealth provider of knock off versions of popular weight loss drugs. (Courtesy Hims & Hers)

Hims & Hers Health , a telehealth platform that sells knockoffs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue.

The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data.

The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million.

Hims & Hers also issued guidance that was in line with expectations. It sees third-quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn’t changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million.

Co-founder and CEO Andrew Dudum said the company believes “it is entering an exciting period of growth where we’ll enter new, high-impact specialties that bring millions of people in need of care into the market.” A broadening offering will help the company move from providing care on a single issue to one where people can proactively manage their overall health, he added.

The company is also known for offering solutions for hair loss, mental health, and sexual health.

One business that has been in the spotlight is its sales of compounded GLP-1, after a messy split with Wegovy maker Novo Nordisk. Now that the official shortage of GLP-1s has come to an end, some have feared a hit to sales for Hims & Hers.

Barron’s recommended shorting the stock on March 6. The stock is up 55% since then.

Write to Liz Moyer at liz.moyer@barrons.com